| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5403833 (Pediatric) | PF PRISM CV | Methods of inhibiting transplant rejecton in mammals using rapamycin and derivatives and prodrugs thereof |
Oct, 2012
(11 years ago) | |
| US5100899 | PF PRISM CV | Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof |
Jul, 2013
(10 years ago) | |
| US5536729 | PF PRISM CV | Rapamycin formulations for oral administration |
Sep, 2013
(10 years ago) | |
|
US5100899 (Pediatric) | PF PRISM CV | Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof |
Jan, 2014
(10 years ago) | |
|
US5536729 (Pediatric) | PF PRISM CV | Rapamycin formulations for oral administration |
Mar, 2014
(10 years ago) | |
| US5989591 | PF PRISM CV | Rapamycin formulations for oral administration |
Mar, 2018
(6 years ago) | |
|
US5989591 (Pediatric) | PF PRISM CV | Rapamycin formulations for oral administration |
Sep, 2018
(5 years ago) | |
Rapamune is owned by Pf Prism Cv.
Rapamune contains Sirolimus.
Rapamune has a total of 7 drug patents out of which 7 drug patents have expired.
Expired drug patents of Rapamune are:
- US5403833*PED
- US5100899
- US5536729
- US5100899*PED
- US5536729*PED
- US5989591
- US5989591*PED
Rapamune was authorised for market use on 25 January, 2010.
Rapamune is available in tablet;oral, solution;oral dosage forms.
Rapamune can be used as inhibiting transplant rejection using rapamycin (sirolimus).
The generics of Rapamune are possible to be released after 28 May, 2022.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | May 28, 2022 |
| Orphan Drug Exclusivity(ODE-92) | May 28, 2022 |
Drugs and Companies using SIROLIMUS ingredient
Market Authorisation Date: 25 January, 2010
Treatment: Inhibiting transplant rejection using rapamycin (sirolimus)
Dosage: TABLET;ORAL; SOLUTION;ORAL
RAPAMUNE family patents
